Infosys collaborates with Nihon Chouzai to expand healthcare access in Japan

Infosys (NSE, BSE, NYSE: INFY), a global leader in next-generation digital services and consulting, today announced its collaboration with Nihon Chouzai (TSE), Japan's leading dispensing pharmacy chain, to expand healthcare access in Japan with enhanced online medication guidance services and payment solutions. As part of this collaboration, Infosys has developed a mobile application, NiCOMS, a pioneering telemedicine service that enables patients to receive remote medication guidance from registered pharmacists, eliminating the need for pharmacy visits.

Nihon Chouzai in collaboration with Infosys launched the web version of NiCOMS in September 2020. With an existing registered userbase of over 1,800,000, the mobile application will now integrate with OkusuriTechoPlus, Nihon Chouzai’s digital medication notebook, by merging the account and authentication processes. Infosys adopted an agile approach to develop the NiCOMS mobile app, allowing the company to nimbly adapt to evolving requirements driven by deregulation and COVID-19. The online medication guidance service on NiCOMS allows patients across Japan to receive medication instructions, consultations, and make payments during video calls with pharmacists. The responsive user interface enhances compatibility across a wide range of terminals, operating systems, and browsers, ensuring accessibility for all users and a smooth experience across devices.

Kunihiko Kurihara, Executive Officer, General Manager of IT Department, NIHON CHOUZAI CO., LTD., said, "Our collaboration with Infosys complements our best-in-class solution and gives it a new scale with the pioneering NiCOMS platform and its ability to bring positive experiences to our customers. What started a few years ago with the web version is now further strengthened by Infosys’ agility and expertise in digital transformation, which has helped us realize our vision for a one-of-a-kind telemedicine service."

Hideyuki Aoki, Vice President, Country Head – Japan, Infosys, said, “Together with Nihon Chouzai, we are forging the future of digital healthcare in Japan through innovative solutions. This alliance will offer enhanced online medical services and increase access to quality pharmaceutical interventions, with an aim towards making significant impact at scale.”

About Nihon Chouzai

Nihon Chouzai is one of the Japan's leading dispensing pharmacy operators with dispensing pharmacies in all prefectures in Japan and approximately 4,000 pharmacists. Since its establishment in 1980, the company has consistently pursued the "Separation of Drug Prescribing and Dispensing Services" to achieve its ideal function and role as a dispensing pharmacy that supports the Japan’s health insurance system, and has aggressively developed its dispensing pharmacy business. In addition to its efforts to promote the use of generic drugs and home medical care, the company has been actively investing in ICT from early on, and is committed to providing high-quality, innovative medical services needed in a hyper-aged society.

Visit https://www.nicho.co.jp/en/ for more information.

About Infosys

Infosys is a global leader in next-generation digital services and consulting. Over 300,000 of our people work to amplify human potential and create the next opportunity for people, businesses and communities. We enable clients in more than 56 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace.

Visit www.infosys.com to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next.

Safe Harbor

Certain statements in this release concerning our future growth prospects, or our future financial or operating performance, are forward-looking statements intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, our ability to attract and retain personnel, our transition to hybrid work model, economic uncertainties, technological innovations such as Generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, our corporate actions including acquisitions, and cybersecurity matters. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2023. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

Media contacts:

For more information, please contact PR_Global@Infosys.com